### UCI <sup>d</sup>Chao Family Comprehensive Cancer Center

# Hepatobiliary and Pancreas Disease-Oriented Team

**Clinical Research Treatment Trial Flowchart** 

www.cancer.uci.edu

Open to Accrual Low Accruing Pending Activation/Suspended **THIRD LINE** LOCOREGIONAL **FIRST LINE** SECOND LINE UCI 22-106 UCI 19-49 STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab Cabo + Ipi/Nivo + TACE (Slot request required) Coord: H. Nguyen Coord: H. Nguyen Accrual: 7/10 Accrual: 19/35 UCI 22-211 UCI 16-94 UCI 23-75/ROUTE 90 MED1572 (IgG1 mAb) ± Bev ± Lenvatinib TATE + Nivolumab (includes gastric/GEJ) Eye90 microspheres Slot request required Coord: C. Kang Coord: M. Duron Coord: M. Duron Accrual: 3/8 Accrual: 28/40 Accrual: 1/15 UCI 23-104 UCI 23-215 Livmoniplimab + Budigalimab AZD5851 (GPC3 Autologous CAR-T) Atezolizumab + Bevacizumab Tremelimumab + Durvalumab Cell therapy audit pending Coord: H. Nguyen Accrual: 3/7 UCI 23-86 Atezolizumab ± Bevacizumab (Child-Pugh B7 and B8) Coord: M. Duron Accrual: 0/10



#### SYSTEMIC + OPERATIVE

EA2197/OPT-IN Gemcitabine + Cisplatin: Neo + Adjuvant or Adjuvant only Incidental gallbladder

> Coord: J. Balangue Accrual: 0/10

#### ETCTN 10608

Gemcitabine + Cisplatin + Durva Neo/Adjuvant for<u>high-</u> risk resectable ICC

> Coord: J. Balangue Accrual: 0/3

#### <u>UCI 23-99</u>

Randomize, adjuvant Rilvegostomig/placebo + capecitabine or gem/cisplatin after BTC resection

> Coord: H. Nguyen Accrual: 0/8

IRST LINE	
1101 22-212	

(includes Ampullary)

Durvalumab + any gemcitabine-based regimen

Coord: H. Nguyen Accrual: 4/8

#### SECOND LINE+

Open to Accrual

ETCTN-10276 M3814 ± Avelumab + Hypofraction Radiation

> Coord: C. Kang Accrual: 3/5

UCI & Chao Family Comprehensive Cancer Center



#### PERIOPERATIVE

<u>A021806</u>

Neo/adjuvant vs adjuvant mFOLFIRINOX

> Coord: J. Balangue Accrual: 0/15

#### <u>UCI 22-75</u>

ELI-002 7P (oncolytic virus) (KRAS Local testing) Within 6 months of resection or last adjuvant treatment

> Coord: M. Duron Accrual: 5/7

BORDERLINE/ LOCALLY ADVANCED

ETCTN-10366 M3814 (Peposertib) + radiation therapy Coord: S. Duong Accrual: 4/8

ETCTN-10464 Olaparib with Durvalumab + radiation therapy

> Coord: S. Duong Accrual: 0/5

UCI 23-134 Padeliporfin Vascular targeted photodynamic therapy

Pancreatic head/uncinate w/SMA

Coord: C. Kang Accrual: 0/8

#### FIRST LINE LA/METASTATIC

S2001 Olaparib +/- Pembrolizumab (BRCA 1/2, STABLE DISEASE)

> Coord: J. Balangue Accrual: 2/4

UCI 23-200 AZD0901 (CLND18 ADC) with NAL-IRI or Gemcitabine Investigator discretion

> Coord: S. Duong Accrual: 3/10

#### SECOND LINE

ETCTN 10522 CA4948 + gemcitabine + nabpaclitaxel

> Coord: H. Nguyen Accrual: 3/4

#### <u>A022106</u>

Nab-paclitaxel + Gemcitabine ± Cisplatin BRCA1/2 or PALB2 PD on 1L FOLFIRINOX

> Coord: J. Balangue Accrual: 0/3

#### **RECURRENT METASTATIC**

UCI 24-08 SPEDOX -6 (Protein encapsulated doxorubicin)


> Coord: TBD Pending PRMC

Review Biomarker Based Solid Tumors Pages 6 and 7

Pancreatic












### Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

Open to Accrual

Accrual: 19/25






Coord: H. Nguyen

Accrual: 4/15



## Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

Open to Accrual Low Accruing Pending Activation/Suspended





November 2024 P- HB Flowchart 7



Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

Open to Accrual Low Accruing Pending Activation/Suspended

UCI 22-26 CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: M. Duron Accrual: 8/12 UCI 23-07 P-MUC1C-ALLO1 (CAR-T Cell)

Epithelial-derived cancer

Coord: J. Miranda Accrual: 0/5



November 2024 P- HB Flowchart 8



#### **BLOOD COLLECTION**

#### <u>UCI 21-124</u>

ctDNA collection during HBP workup

> Coord: S.Duong Accrual: 14/17

#### UCI 23-10/PRECEDE

(Blood collection for early detection of pancreatic cancer)

Pending budget/contract

